Aruvant Sciences

Aruvant Sciences is a clinical-stage gene therapy company focused on hematological disorders, dedicated to helping patients with sickle cell disease and β-thalassemia. The company's lead candidate, ARU-1801, is a lentiviral gene therapy targeting sickle cell disease and transfusion-dependent β-thalassemia. ARU-1801 incorporates a patented gene payload designed to deliver modified γ-globin through a proprietary vector construct into autologous stem cells, with the goal of restoring normal red blood cell function by increasing levels of fetal hemoglobin. The high potency of the modified gamma-globin enables ARU-1801 to be transplanted with reduced-intensity conditioning (RIC).